Free Trial
NASDAQ:LYEL

Lyell Immunopharma (LYEL) Stock Price, News & Analysis

Lyell Immunopharma logo
$0.45 -0.02 (-3.60%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$0.45 0.00 (-0.93%)
As of 04/25/2025 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lyell Immunopharma Stock (NASDAQ:LYEL)

Key Stats

Today's Range
$0.42
$0.48
50-Day Range
$0.41
$0.74
52-Week Range
$0.39
$2.88
Volume
612,635 shs
Average Volume
1.04 million shs
Market Capitalization
$132.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.00
Consensus Rating
Reduce

Company Overview

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Lyell Immunopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

LYEL MarketRank™: 

Lyell Immunopharma scored higher than 66% of companies evaluated by MarketBeat, and ranked 287th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lyell Immunopharma has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    Lyell Immunopharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Lyell Immunopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Lyell Immunopharma are expected to grow in the coming year, from ($0.78) to ($0.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lyell Immunopharma is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lyell Immunopharma is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lyell Immunopharma has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Lyell Immunopharma's valuation and earnings.
  • Percentage of Shares Shorted

    4.57% of the float of Lyell Immunopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lyell Immunopharma has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Lyell Immunopharma has recently decreased by 4.52%, indicating that investor sentiment is improving.
  • Dividend Yield

    Lyell Immunopharma does not currently pay a dividend.

  • Dividend Growth

    Lyell Immunopharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.57% of the float of Lyell Immunopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Lyell Immunopharma has a short interest ratio ("days to cover") of 5.7.
  • Change versus previous month

    Short interest in Lyell Immunopharma has recently decreased by 4.52%, indicating that investor sentiment is improving.
  • News Sentiment

    Lyell Immunopharma has a news sentiment score of 1.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Lyell Immunopharma this week, compared to 2 articles on an average week.
  • Search Interest

    3 people have searched for LYEL on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Lyell Immunopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lyell Immunopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $449,508.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    25.10% of the stock of Lyell Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    66.05% of the stock of Lyell Immunopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lyell Immunopharma's insider trading history.
Receive LYEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lyell Immunopharma and its competitors with MarketBeat's FREE daily newsletter.

LYEL Stock News Headlines

Lyell Immunopharma announces FDA granted RMAT designation to LYL314
2025 could be "worse than the dot-com bust", says man who predicted 2008 banking crisis
What's coming next to the U.S. market could be worse than anything we've ever seen before – worse than the dot-com bust, worse than the COVID crash, and even worse than the Great Depression. What's coming, he says, could soon crash the market by 50% or more – and keep it down for 10, 20, or even 30 years.
See More Headlines

LYEL Stock Analysis - Frequently Asked Questions

Lyell Immunopharma's stock was trading at $0.64 at the beginning of the year. Since then, LYEL stock has decreased by 29.7% and is now trading at $0.4502.
View the best growth stocks for 2025 here
.

Lyell Immunopharma, Inc. (NASDAQ:LYEL) announced its quarterly earnings results on Wednesday, March, 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by $0.52. The company had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative trailing twelve-month return on equity of 34.64%.

Lyell Immunopharma (LYEL) raised $425 million in an initial public offering on Thursday, June 17th 2021. The company issued 25,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, BofA Securities, J.P. Morgan and Morgan Stanley served as the underwriters for the IPO.

Top institutional investors of Lyell Immunopharma include Exchange Traded Concepts LLC (0.08%) and Rhumbline Advisers (0.08%). Insiders that own company stock include Richard Klausner, Lynn Seely, Sumant Ramachandra, Charles W Newton and Otis W Brawley.
View institutional ownership trends
.

Shares of LYEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lyell Immunopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Broadcom (AVGO), Invesco QQQ (QQQ) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
3/12/2025
Today
4/25/2025
Next Earnings (Estimated)
5/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:LYEL
Fax
N/A
Employees
270
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.00
High Stock Price Target
$1.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+122.1%
Consensus Rating
Reduce
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-234,630,000.00
Net Margins
-323,792.09%
Pretax Margin
-323,792.09%

Debt

Sales & Book Value

Annual Sales
$61,000.00
Price / Cash Flow
N/A
Book Value
$2.60 per share
Price / Book
0.17

Miscellaneous

Free Float
218,829,000
Market Cap
$132.94 million
Optionable
Optionable
Beta
-0.26
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:LYEL) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners